salvinorin a has been researched along with (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol in 1 studies
| Studies (salvinorin a) | Trials (salvinorin a) | Recent Studies (post-2010) (salvinorin a) | Studies ((5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol) | Trials ((5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol) | Recent Studies (post-2010) ((5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol) |
|---|---|---|---|---|---|
| 247 | 7 | 128 | 141 | 3 | 138 |
| Protein | Taxonomy | salvinorin a (IC50) | (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (IC50) |
|---|---|---|---|
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | 5.577 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 4.5885 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0179 | |
| Rapamycin-insensitive companion of mTOR | Homo sapiens (human) | 0.0028 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.0139 | |
| Target of rapamycin complex 2 subunit MAPKAP1 | Homo sapiens (human) | 0.0028 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.0102 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
1 other study(ies) available for salvinorin a and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
| Article | Year |
|---|---|
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |